Anup Joseph Devasia

Welcome to Toronto @allmyelomadocs vimeo.com/1059879940?fl=…

@trivedi2492 @OffCMCVellore @MathewsVikram @udaypkulkarni Congrats @trivedi2492

Work done at Christian Medical College Vellore. Almost comparable outcome with single agent Low dose Nivolumab in Relapsed Refractory settings. Where Less is More. @OffCMCVellore @MathewsVikram @udaypkulkarni #ASH

Groundbreaking first-in-human study published in NEJM, and presented at ASH 2024 - Lentiviral gene therapy in Hemophilia A. Congrats Dr. Alok Srivastava and team @cmcvelloreoff @OffCMCVellore

On being a good doctor. The number of research publications don’t tell you how good a doctor is at being a doctor. Neither do the number of book chapters or grants. Or academic rank. It’s a different skill set. Good doctors have stellar clinical acumen & empathy. #MedTwitter

Dr Alok Srivastava honoured at ISTH. His seminal works in Hemophilia, thrombosis & gene therapy has not only imparted knowledge but also instilled values, ignited curiosity, and fostered a love for learning that will endure for generations... Proud to be your student sir !

@ProfMakris @MushtaqBilalPhD Is this for real? so embarrassing . More so that the authors never bothered to read it

How embarrassing that this is published in a scientific journal! Below are just two pages from the paper. Have a look at the paragraph before the conclusion! Thank you @MushtaqBilalPhD for alerting us to this. #AI #Publishing #ScientificCommunication.

@baxirahul was a must buy for all melas and festivals.

Does this remind you of your childhood? We had such simple toys. Found this outside a railway station and got it home to relive the memories.

@Rfonsi1 DaraKRd if high risk , otherwise DRVd ASCT definitely upfront if eligible DRd if TIE

For patients with active myeloma, the choices for frontline therapy have been greatly simplified in 2024: - All patients should be treated with Daratumumab-Rd - There are only two remaining questions: 1* Should I also use a PI, and if so which one? (K vs V) 2* Should the patient be offered stem cell transplant? That is all! #mmsm

@baxirahul me

Morning joys. Any fountain pen users here?

Attending #Targets23? In the latest issue, @dranupjdevasia, Lancman, and @akeithstewart discuss the landmark Cancer Research article that introduced proteasome inhibition in #myeloma. bit.ly/45qyTmp @pmcancercentre @AACR

@jayastuMD @DrHKantarjian @ASCO @MDAndersonNews @NitinJainMD @TapKadia @Daver_Leukemia @NicholasShortMD @bose_prithviraj @FadiHaddad_MD @DanielleHammo20 @VivekSubbiah @SocietyofHemOnc @doctorpemm truly deserving @DrHKantarjian . Congratulations

@VincentRK @MayoClinic @MayoMyeloma @MayoCancerCare @myelomaMD @ADispenzieri @MyelomaDrKapoor @lbaughn Happy bday Dr. Kyle. You are one in a million

We are celebrating Bob Kyle’s 95th Birthday today. @MayoClinic @MayoMyeloma @MayoCancerCare Picture taken today at The Foundation House at Mayo Clinic. 1/

@HCC_HemeCancer @pb10_bmt @udaypkulkarni @madhavi_maddali @MedTweetorials @ManjuSengar7 @MathewsVikram @faheema_hasan @DrNikitaMehra @chepsyphilip @punitjn @NancyArthurPhD @jayastuMD @DrArunCMC nytimes.com/1999/11/18/us/…

@pb10_bmt @udaypkulkarni @madhavi_maddali @MedTweetorials #MultipleMyelomaAwarenessMonth

March is Myeloma Awareness month and here is a short video on the history of this disease. #hcc #leusm #mmsm #myeloma Though documented eons ago, the 1st well-documented case is of Sarah Newbury by Dr. Solly in 1844 calling it Mollities ossium: Pathological softening of the bone

@HCC_HemeCancer @pb10_bmt @udaypkulkarni @madhavi_maddali @MedTweetorials @ManjuSengar7 @MathewsVikram @faheema_hasan @DrNikitaMehra @chepsyphilip @punitjn @NancyArthurPhD @jayastuMD @DrArunCMC Kappa and Lambda: Leonhard Korngold and his technician Rose Lipari (from Memorial Sloan Kettering Hospital), identified different class of Bence Jones proteins. As a tribute to Korngold & Lipari, these proteins were later named as Kappa and Lamda.

@VUMolekule @HCC_HemeCancer @nihardesai7 @faheema_hasan @drsanjeev1980 @punitjn CART is not available for immediate use. Takes 4-6 weeks for manufacturing. The biggest challenge is many manufacturing units are overwhelmed with the production of CARTs. It is a one time infusion and then monitor. Bispecifics are available readily, but has to be continued

@dranupjdevasia @HCC_HemeCancer @nihardesai7 @faheema_hasan @drsanjeev1980 @punitjn Just curious, how is now the decision made to choose between teclistamab and CAR-Ts?

FDA Grants Priority Review to the bispecific antibody Elranatamab in Relapsed/Refractory Myeloma 👉supported by findings from the phase 2 MagnetisMM-3 trial @NoopurRajeMD @MathewsVikram @ManjuSengar7 @DrPMPGI @MedTweetorials #mmsm onclive.com/view/fda-grant…

@drsanjeev1980 @HCC_HemeCancer @nihardesai7 @faheema_hasan @punitjn More than availability , it is accessibility that is important. Daratumumab is available, how many can access it

@dranupjdevasia @HCC_HemeCancer @nihardesai7 @faheema_hasan @punitjn Teclistamab will be available in India soon,

@nihardesai7 @drsanjeev1980 @HCC_HemeCancer @faheema_hasan @punitjn Very true. Majority are on monthly IVIG prophylaxis which will add on to the cost

@drsanjeev1980 @dranupjdevasia @HCC_HemeCancer @faheema_hasan @punitjn We must be very cautious of this 👇🏻 twitter.com/HadidiSamer/st…